Objective To investigate the efficacy of sertraline hydrochloride combined with mesalazine in the treatment of patients with ulcerative colitis complicated with depression .Methods From March 2014 to March 2015 ,eighty patients with mild active ulcerative colitis ,self‐rating depression scale (SDS) score between > 53 and 70 points ,were enrolled .Eighty patients were divided into sertraline hydrochloride combined with mesalazine group and mesalazine group (control group) ,40 patients in each group .SDS questionnaire and gastrointestinal endoscopy were applied at the beginning of the study and 12 weeks after treatment to evaluate the efficacy .Chi square test or t test was performed for statistical analysis .Results After 12 weeks treatment ,the efficacy of mesalazine combined with sertraline group and mesalazine group was 75% (30/40) and 65% (26/40) , respectively ,and the difference was not statistically significant ( P > 0 .05 ) .Before the treatment ,ulcerative colitis activity index (UCAI) of mesalazine combined with sertraline group and mesalazine group was 13 .13 ± 4 .41 and 12 .41 ± 3 .96 , respectively ;12 weeks after treatment ,the UCAI of the two groups were 7 .29 ± 5 .78 and 8 .60 ± 4 .56 , respectively .The UCAI of both the two groups were lower than those before treatment , and the differences were statistically significant (t= 6 .106 7 and 5 .189 3 ,both P < 0 .01) .The difference was not statistically significant in UCAI between the two groups after treatment (P > 0 .05) .Before treatment ,SDS score of mesalazine combined with sertraline group and mesalazine group was 55 .98 ± 9 .61 and 56 .27 ± 8 .45 , respectively ;12 weeks after treatment ,SDS scores of the two groups were 49 .36 ± 4 .51 and 52 .81 ± 6 .11 ,respectively .Compared with those before treatment , after 12 weeks treatment , SDS scores of mesalazine combined with sertraline group and mesalazine group both decreased (t= 3 .944 0 ,P= 0 .000 2 ;t=2 .098 6 ,P= 0 .039 1) .After treatment ,SDS score of mesalazine combined with sertraline group was lower than that of mesalazine group (t = 2 .873 2 , P = 0 .005 2) .Conclusion Routine ulcerative colitis treatment combined with sertraline hydrochloride in ulcerative colitis can significantly improve depression of ulcerative colitis patients and improve the quality of patients′ life .

OBJECTIVE: To investigate the anti-inflammatory effect and mechanisms of interleukin-35 (IL-35) in inflammatory bowel disease. METHODS: BALB/c mice were divided into three groups with 10 mice in each group:control group, model group (oral administration of 4% glucan sodium sulfate for 7 d) and IL-35-treated group (oral administration of 4% glucan sodium sulfate for 7 d, intraperitoneal injection of 2 μg IL-35 at d2-5). Disease activity index (DAI) was scored every day. After 7 d, the mice were sacrificed, and the serum and intestinal tissue samples were collected. The gross morphology of the colon was observed; HE staining was used to observe the pathological changes of colon tissue; flow cytometry was employed to detect the change of macrophage polarization ratio in colon tissue; the mRNA expression levels of cytokines IL-6, TNF-α, IFN-γ, IL-10 and SHIP1 in colon tissue were determined by real-time quantitative RT-PCR; the expression and distribution of SHIP1 in colon tissue was measured by immunohistochemistry; Western blotting was adopted to detect the expression level of SHIP1 protein in colonic intestinal tissues of each group. RESULTS: The DAI scores of the mice in the model group were higher than those in the control group, while the DAI scores in the IL-35-treated group were lower than those in the model group (all <0.01). Compared with the control group, the colon length was significantly shortened in the model group (<0.05), while the colon length of the IL-35-treated group had an increasing trend compared with the model group, but the difference was not statistically significant (>0.05). Compared with the model group, microscopic inflammatory infiltration score was decreased and microscopic crypt destruction and score was significantly lower in IL-35-treated group (all <0.05). The relative expression of proinflammatory cytokines IL-6, TNF-α and IFN-γ in the colon tissue of IL-35-treated group was decreased compared with the model group, while the relative expression of IL-10 mRNA was higher than that of the model group (all <0.05). Compared with the control group, the proportion of M1 macrophages in the model group increased (<0.05), while the proportion of M1 macrophages in the IL-35-treated group was lower than that in the model group (<0.05). The relative expression of SHIP1 mRNA and protein in the colon tissue of IL-35-treated group was higher than that in the model group (all <0.05). CONCLUSIONS IL-35 can inhibit the polarization of M1 macrophages and regulate inflammatory cytokines to promote anti-inflammatory effect on mice with colitis.
Animals ; Anti-Inflammatory Agents ; pharmacology ; Colitis ; drug therapy ; physiopathology ; Colon ; drug effects ; Cytokines ; genetics ; Disease Models, Animal ; Gene Expression Regulation ; drug effects ; Glucans ; pharmacology ; Interleukin-6 ; genetics ; Interleukins ; pharmacology ; Macrophages ; drug effects ; Mice ; Mice, Inbred BALB C ; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases ; genetics